Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2015-01-09)Premium Content

Abbvie Inc (ABBV)

2015-01-30@21:55:06 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-30@21:28:50 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-30@20:35:51 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-30@18:00:50 ET
AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan (EUR)

2015-01-30@18:00:00 ET
AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan (PRN)

2015-01-30@11:34:26 ET
8-K: AbbVie Inc. (EDK)

2015-01-30@08:45:00 ET
Technical Commentary on Pharma Stocks -- Merck, AbbVie, Bristol-Myers Squibb, Shire, and Mallinckrodt (PRN)

2015-01-30@07:54:18 ET
AbbVie Reaffirms (SEG)

2015-01-30@07:48:29 ET
AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results (EUR)

2015-01-30@07:47:00 ET
AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results (PRN)

2015-01-24@20:39:39 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-23@20:45:27 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-20@13:01:02 ET
AbbVie Innovation Center Opens at the University of Illinois-Urbana Research Park (BIZ)

2015-01-20@05:14:06 ET
AbbVie receives marketing authorizations from EC for HCV infection drug (DTM)

2015-01-19@08:22:23 ET
AbbVie announces licensing of VIEKIRAX and EXVIERA in the UK for genotype 1 (GT1) chronic hepatitis C virus (HCV) infection (MTO)

2015-01-19@04:41:18 ET
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir) and EXVIERA(R) (dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C (EUR)

2015-01-17@20:35:33 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-16@20:35:45 ET
AbbVie Inc.Corporate Event Announcement Notice (WSH)

2015-01-16@18:11:00 ET
AbbVie announces guidance for 2015 (DTM)

2015-01-16@10:08:00 ET
AbbVie Announces U.S. FDA Approval of DUOPA(TM) (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease (PRN)